Vorozole
Jump to navigation
Jump to search
Clinical data | |
---|---|
Other names | R-76713; Rizivor |
ATC code | |
Pharmacokinetic data | |
Bioavailability | Very high |
Metabolism | Hepatic |
Elimination half-life | 8 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H13ClN6 |
Molar mass | 324.77 g·mol−1 |
3D model (JSmol) | |
| |
(what is this?) (verify) |
Vorozole (developmental code name R-76713; former tentative brand name Rizivor) is a triazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.[1]
References
- ^ Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Research and Treatment. 49. 49 (Suppl 1): S59-65, discussion S73-7. doi:10.1023/a:1006052923468. PMID 9797019. S2CID 28231447.
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles with changed CASNo identifier
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Aromatase inhibitors
- Benzotriazoles
- Chloroarenes
- Triazoles
- All stub articles
- Antineoplastic and immunomodulating drug stubs